{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:06:18Z","timestamp":1783469178624,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","award":["CAMS-2017-I2M-1-002"],"award-info":[{"award-number":["CAMS-2017-I2M-1-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13048-019-0560-y","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T09:47:37Z","timestamp":1567244857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study"],"prefix":"10.1186","volume":"12","author":[{"given":"Wenhui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8723-3461","authenticated-orcid":false,"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,31]]},"reference":[{"key":"560_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ygyno.2008.09.041","volume":"112","author":"S Tangjitgamol","year":"2009","unstructured":"Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P. Interval debulking surgery for advanced epithelial ovarian cancer: a Cochrane systematic review. Gynecol Oncol. 2009;112:257\u201364. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2008.09.041\n                    \n                  .","journal-title":"Gynecol Oncol"},{"key":"560_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21387\n                    \n                  .","journal-title":"CA Cancer J Clin"},{"key":"560_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115\u201332. \n                    https:\/\/doi.org\/10.3322\/caac.21338\n                    \n                  .","journal-title":"CA Cancer J Clin"},{"issue":"7239","key":"560_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nature07943","volume":"458","author":"Michael R. Stratton","year":"2009","unstructured":"Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009;458:719\u2013724. nature07943 [pii] \n                    https:\/\/doi.org\/10.1038\/nature07943\n                    \n                  .","journal-title":"Nature"},{"key":"560_CR5","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1126\/science.1204040331\/6024\/1553","volume":"331","author":"MR Stratton","year":"2011","unstructured":"Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science. 2011;331:1553\u20138. \n                    https:\/\/doi.org\/10.1126\/science.1204040331\/6024\/1553\n                    \n                   [pii].","journal-title":"Science"},{"key":"560_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.critrevonc.2008.06.003","volume":"69","author":"A Russo","year":"2009","unstructured":"Russo A, Calo V, Bruno L, Rizzo S, Bazan V, Di Fede G. Hereditary ovarian cancer. Crit Rev Oncol Hematol. 2009;69:28\u201344. \n                    https:\/\/doi.org\/10.1016\/j.critrevonc.2008.06.003\n                    \n                  .","journal-title":"Crit Rev Oncol Hematol"},{"key":"560_CR7","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1002\/1097-0142(19941015)74:8<2341::AID-CNCR2820740819>3.0.CO;2-Z","volume":"74","author":"SA Narod","year":"1994","unstructured":"Narod SA, Madlensky L, Bradley L, Cole D, Tonin P, Rosen B, Risch HA. Hereditary and familial ovarian cancer in southern Ontario. Cancer. 1994;74:2341\u20136.","journal-title":"Cancer"},{"key":"560_CR8","doi-asserted-by":"publisher","unstructured":"Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609\u201315. \n                    https:\/\/doi.org\/10.1038\/nature10166\n                    \n                   nature10166 [pii].","DOI":"10.1038\/nature10166"},{"key":"560_CR9","doi-asserted-by":"publisher","unstructured":"Kanchi KL, Johnson KJ, Lu C, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun 2014;5:3156. \n                    https:\/\/doi.org\/10.1038\/ncomms4156\n                    \n                   ncomms4156 [pii].","DOI":"10.1038\/ncomms4156"},{"key":"560_CR10","first-page":"678","volume":"52","author":"DF Easton","year":"1993","unstructured":"Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium Am J Hum Genet. 1993;52:678\u2013701.","journal-title":"The Breast Cancer Linkage Consortium Am J Hum Genet"},{"key":"560_CR11","first-page":"589","volume":"59","author":"HT Lynch","year":"1982","unstructured":"Lynch HT, Albano WA, Lynch JF, Lynch PM, Campbell A. Surveillance and management of patients at high genetic risk for ovarian carcinoma. Obstet Gynecol. 1982;59:589\u201396.","journal-title":"Obstet Gynecol"},{"key":"560_CR12","doi-asserted-by":"publisher","first-page":"18032","DOI":"10.1073\/pnas.1115052108","volume":"108","author":"T Walsh","year":"2011","unstructured":"Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108:18032\u20137. \n                    https:\/\/doi.org\/10.1073\/pnas.1115052108\n                    \n                  .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"560_CR13","doi-asserted-by":"publisher","unstructured":"Alsop K, Fereday S, Meldrum C, et al. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. J Clin Oncol 2012;30:2654\u201363. https:\/\/doi: JCO.2011.39.8545 [pii] \n                    https:\/\/doi.org\/10.1200\/JCO.2011.39.8545","DOI":"10.1200\/JCO.2011.39.8545"},{"key":"560_CR14","unstructured":"Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology (Williston Park) 1998;12:399\u2013406; discussion 9\u201310, 13. https:\/\/doi:173180 [pii]."},{"key":"560_CR15","doi-asserted-by":"publisher","unstructured":"Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700\u201310. https:\/\/doi: S0002\u20139297(07)63109\u20137 [pii]\n                    https:\/\/doi.org\/10.1086\/318787","DOI":"10.1086\/318787"},{"key":"560_CR16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0002-9610(00)00460-8","volume":"180","author":"ET Matloff","year":"2000","unstructured":"Matloff ET. The breast surgeon's role in BRCA1 and BRCA2 testing. Am J Surg. 2000;180:294\u20138.","journal-title":"Am J Surg"},{"key":"560_CR17","doi-asserted-by":"publisher","unstructured":"Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11:685\u201396. https:\/\/doi:nrg2841 [pii]. \n                    https:\/\/doi.org\/10.1038\/nrg2841\n                    \n                  .","DOI":"10.1038\/nrg2841"},{"key":"560_CR18","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/modpathol.2012.62","volume":"25","author":"CS Ku","year":"2012","unstructured":"Ku CS, Cooper DN, Wu M, Roukos DH, Pawitan Y, Soong R, Iacopetta B. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol. 2012;25:1055\u201368. \n                    https:\/\/doi.org\/10.1038\/modpathol.2012.62\n                    \n                   modpathol201262 [pii].","journal-title":"Mod Pathol"},{"key":"560_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10689-014-9749-9","volume":"14","author":"Y Guan","year":"2015","unstructured":"Guan Y, Hu H, Peng Y, et al. Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing. Familial Cancer. 2015;14:9\u201318. \n                    https:\/\/doi.org\/10.1007\/s10689-014-9749-9\n                    \n                  .","journal-title":"Familial Cancer"},{"key":"560_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324. \n                    https:\/\/doi.org\/10.1038\/gim.2015.30\n                    \n                   gim201530 [pii].","journal-title":"Genet Med"},{"key":"560_CR21","doi-asserted-by":"publisher","first-page":"12629","DOI":"10.1073\/pnas.10079831071007983107","volume":"107","author":"T Walsh","year":"2010","unstructured":"Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, Nord AS, Mandell JB, Swisher EM, King MC. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A. 2010;107:12629\u201333. \n                    https:\/\/doi.org\/10.1073\/pnas.10079831071007983107\n                    \n                   [pii].","journal-title":"Proc Natl Acad Sci U S A"},{"key":"560_CR22","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1097\/IGC.0000000000001065","volume":"27","author":"X Wu","year":"2017","unstructured":"Wu X, Wu L, Kong B, et al. The first Nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian Cancer patients. Int J Gynecol Cancer. 2017;27:1650\u20137. \n                    https:\/\/doi.org\/10.1097\/IGC.0000000000001065\n                    \n                  .","journal-title":"Int J Gynecol Cancer"},{"key":"560_CR23","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","volume":"283","author":"J Boyd","year":"2000","unstructured":"Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260\u20135.","journal-title":"JAMA"},{"key":"560_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cancergen.2014.05.002","volume":"207","author":"R Janavicius","year":"2014","unstructured":"Janavicius R, Rudaitis V, Mickys U, Elsakov P, Griskevicius L. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania. Cancer Genet. 2014;207:195\u2013205. \n                    https:\/\/doi.org\/10.1016\/j.cancergen.2014.05.002\n                    \n                  .","journal-title":"Cancer Genet"},{"key":"560_CR25","doi-asserted-by":"publisher","unstructured":"Lee JS, John EM, McGuire V, Felberg A, Ostrow KL, DiCioccio RA, Li FP, Miron A, West DW, Whittemore AS. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomark Prev. 2006;15:359\u201363. https:\/\/doi:15\/2\/359 [pii]. \n                    https:\/\/doi.org\/10.1158\/1055-9965.EPI-05-0687\n                    \n                  .","DOI":"10.1158\/1055-9965.EPI-05-0687"},{"key":"560_CR26","doi-asserted-by":"crossref","unstructured":"Liede A, Malik IA, Aziz Z, Rios Pd Pde L, Kwan E, Narod SA. Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet 2002;71:595\u2013606. https:\/\/doi: S0002-9297(07)60339-5 [pii].","DOI":"10.1086\/342506"},{"key":"560_CR27","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00432-009-0607-3","volume":"135","author":"MC Lim","year":"2009","unstructured":"Lim MC, Kang S, Seo SS, Kong SY, Lee BY, Lee SK, Park SY. BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients. J Cancer Res Clin Oncol. 2009;135:1593\u20139. \n                    https:\/\/doi.org\/10.1007\/s00432-009-0607-3\n                    \n                  .","journal-title":"J Cancer Res Clin Oncol"},{"key":"560_CR28","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/ijc.11338","volume":"106","author":"J Menkiszak","year":"2003","unstructured":"Menkiszak J, Gronwald J, Gorski B, et al. Hereditary ovarian cancer in Poland. Int J Cancer. 2003;106:942\u20135. \n                    https:\/\/doi.org\/10.1002\/ijc.11338\n                    \n                  .","journal-title":"Int J Cancer"},{"key":"560_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/nejm200107263450401","volume":"345","author":"B Modan","year":"2001","unstructured":"Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, Ben-Baruch G, Fishman A, Menczer J, Struewing JP, Tucker MA, Wacholder S. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:235\u201340. \n                    https:\/\/doi.org\/10.1056\/nejm200107263450401\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"560_CR30","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1002\/cncr.21536","volume":"104","author":"T Pal","year":"2005","unstructured":"Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104:2807\u201316. \n                    https:\/\/doi.org\/10.1002\/cncr.21536\n                    \n                  .","journal-title":"Cancer"},{"key":"560_CR31","doi-asserted-by":"publisher","unstructured":"Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98:1694\u2013706. https:\/\/doi:98\/23\/1694 [pii]. \n                    https:\/\/doi.org\/10.1093\/jnci\/djj465\n                    \n                  .","DOI":"10.1093\/jnci\/djj465"},{"key":"560_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ygyno.2011.10.027","volume":"124","author":"AO Rodriguez","year":"2012","unstructured":"Rodriguez AO, Llacuachaqui M, Pardo GG, Royer R, Larson G, Weitzel JN, Narod SA. BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol. 2012;124:236\u201343. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2011.10.027\n                    \n                  .","journal-title":"Gynecol Oncol"},{"key":"560_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/cncr.29707","volume":"122","author":"I Sakamoto","year":"2016","unstructured":"Sakamoto I, Hirotsu Y, Nakagomi H, Ouchi H, Ikegami A, Teramoto K, Amemiya K, Mochizuki H, Omata M. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer. Cancer. 2016;122:84\u201390. \n                    https:\/\/doi.org\/10.1002\/cncr.29707\n                    \n                  .","journal-title":"Cancer"},{"key":"560_CR34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/sj.ejhg.5200652","volume":"9","author":"L Sarantaus","year":"2001","unstructured":"Sarantaus L, Vahteristo P, Bloom E, Tamminen A, Unkila-Kallio L, Butzow R, Nevanlinna H. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients. Eur J Hum Genet. 2001;9:424\u201330. \n                    https:\/\/doi.org\/10.1038\/sj.ejhg.5200652\n                    \n                  .","journal-title":"Eur J Hum Genet"},{"key":"560_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058182","volume":"8","author":"AV Stavropoulou","year":"2013","unstructured":"Stavropoulou AV, Fostira F, Pertesi M, et al. Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. PLoS One. 2013;8:e58182. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0058182\n                    \n                  .","journal-title":"PLoS One"},{"key":"560_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1006\/gyno.2000.5848","volume":"78","author":"DH Tobias","year":"2000","unstructured":"Tobias DH, Eng C, McCurdy LD, Kalir T, Mandelli J, Dottino PR, Cohen CJ. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. Gynecol Oncol. 2000;78:148\u201351. \n                    https:\/\/doi.org\/10.1006\/gyno.2000.5848\n                    \n                  .","journal-title":"Gynecol Oncol"},{"key":"560_CR37","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1034\/j.1399-0004.1999.550504.x","volume":"55","author":"PN Tonin","year":"1999","unstructured":"Tonin PN, Mes-Masson AM, Narod SA, Ghadirian P, Provencher D. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet. 1999;55:318\u201324.","journal-title":"Clin Genet"},{"key":"560_CR38","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<737::AID-IJC21>3.0.CO;2-1","volume":"86","author":"M Van Der Looij","year":"2000","unstructured":"Van Der Looij M, Szabo C, Besznyak I, Liszka G, Csokay B, Pulay T, Toth J, Devilee P, King MC, Olah E. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer. 2000;86:737\u201340.","journal-title":"Int J Cancer"},{"key":"560_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","volume":"121","author":"S Zhang","year":"2011","unstructured":"Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121:353\u20137. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2011.01.020\n                    \n                  .","journal-title":"Gynecol Oncol"},{"key":"560_CR40","unstructured":"SGO Clinical Practice Statement: Next generation Cancer gene panels versus gene by gene testing. Mar 2014. \n                    https:\/\/www.sgo.org\/clinical-practice\/guidelines\/next-generation-cancer-gene-panels-versus-gene-by-gene-testing\/\n                    \n                  ."},{"key":"560_CR41","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Genetic\/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2019 - July 30, 2018. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf\n                    \n                  ."},{"key":"560_CR42","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc2693","volume":"9","author":"R Brosh","year":"2009","unstructured":"Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009;9:701\u201313. \n                    https:\/\/doi.org\/10.1038\/nrc2693\n                    \n                  .","journal-title":"Nat Rev Cancer"},{"key":"560_CR43","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ygyno.2010.02.012","volume":"117","author":"E Despierre","year":"2010","unstructured":"Despierre E, Lambrechts D, Neven P, Amant F, Lambrechts S, Vergote I. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol. 2010;117:358\u201365. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2010.02.012\n                    \n                  .","journal-title":"Gynecol Oncol"},{"key":"560_CR44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.7399\/fh.10904","volume":"42","author":"L Delgado-Ortega","year":"2018","unstructured":"Delgado-Ortega L, Gines Rubio J, Garcias de Espana MDC, Carcedo D, Cordero Puentes L, Moya de Alarcon C. Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain. Farm Hosp. 2018;42:95\u2013102. \n                    https:\/\/doi.org\/10.7399\/fh.10904\n                    \n                  .","journal-title":"Farm Hosp"},{"key":"560_CR45","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1517\/14656566.2016.1165205","volume":"17","author":"J McLachlan","year":"2016","unstructured":"McLachlan J, Banerjee S. Olaparib for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother. 2016;17:995\u20131003. \n                    https:\/\/doi.org\/10.1517\/14656566.2016.1165205\n                    \n                  .","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"560_CR46","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"Kathryn P. Pennington","year":"2013","unstructured":"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014;20:764\u201375. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2287\n                    \n                   1078\u20130432.CCR-13-2287 [pii].","journal-title":"Clinical Cancer Research"},{"key":"560_CR47","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/jmedgenet-2016-103800","volume":"53","author":"R Manchanda","year":"2016","unstructured":"Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis. J Med Genet. 2016;53:591\u20139. \n                    https:\/\/doi.org\/10.1136\/jmedgenet-2016-103800\n                    \n                   jmedgenet-2016-103800 [pii].","journal-title":"J Med Genet"},{"key":"560_CR48","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/cncr.11310","volume":"97","author":"I Cass","year":"2003","unstructured":"Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2187\u201395. \n                    https:\/\/doi.org\/10.1002\/cncr.11310\n                    \n                  .","journal-title":"Cancer"},{"key":"560_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/jco.2007.11.6905","volume":"26","author":"A Chetrit","year":"2008","unstructured":"Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian Cancer: the National Israeli Study of ovarian Cancer. J Clin Oncol. 2008;26:20\u20135. \n                    https:\/\/doi.org\/10.1200\/jco.2007.11.6905\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"560_CR50","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1200\/jco.2008.16.1703","volume":"26","author":"DS Tan","year":"2008","unstructured":"Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME. \"BRCAness\" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26:5530\u20136. \n                    https:\/\/doi.org\/10.1200\/jco.2008.16.1703\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"560_CR51","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jama.2012.20","volume":"307","author":"KL Bolton","year":"2012","unstructured":"Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307:382\u201390. \n                    https:\/\/doi.org\/10.1001\/jama.2012.20\n                    \n                  .","journal-title":"JAMA"},{"key":"560_CR52","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1158\/1055-9965.epi-16-0286","volume":"25","author":"F Dong","year":"2016","unstructured":"Dong F, Davineni PK, Howitt BE, Beck AH. A BRCA1\/2 mutational signature and survival in ovarian high-grade serous carcinoma. Cancer Epidemiol Biomark Prev. 2016;25:1511\u20136. \n                    https:\/\/doi.org\/10.1158\/1055-9965.epi-16-0286\n                    \n                  .","journal-title":"Cancer Epidemiol Biomark Prev"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0560-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-019-0560-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0560-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T23:08:27Z","timestamp":1598742507000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0560-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,31]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0560-y","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,31]]},"assertion":[{"value":"18 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Review Board of PUMCH has approved this study (HS-1245), and all participants had given their consents before enrollment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consents for publication have been obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}